WASHINGTON — President Donald Trump announced a deal Thursday to cut prices and expand coverage on popular weight-loss drugs Zepbound and Wegovy.

Earlier this week , people familiar with the discussions told The Wall Street Journal the agreement involved Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both GLP-1 medications that currently list for over $1,000 a month without insurance.

The reported deal would make the lowest doses of the drugs available through the administration’s TrumpRx initiative for as little as $149 a month in some cases.

Coverage of the drugs for obesity will expand to Medicare patients starting next year, according to the administration, which said some lower prices also will be phased in for patients without coverage. Starting doses of new, pill versions of th

See Full Page